211 related articles for article (PubMed ID: 37460053)
1. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.
Li Q; Chen K; Zhang T; Jiang D; Chen L; Jiang J; Zhang C; Li S
Eur J Pharmacol; 2023 Sep; 955():175913. PubMed ID: 37460053
[TBL] [Abstract][Full Text] [Related]
2. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
3. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
[TBL] [Abstract][Full Text] [Related]
5. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
6. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
8. Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy.
Mu M; Huang CX; Qu C; Li PL; Wu XN; Yao W; Shen C; Huang R; Wan CC; Jian ZW; Zheng L; Wu RQ; Lao XM; Kuang DM
Cancer Res; 2024 Mar; 84(6):841-854. PubMed ID: 38231484
[TBL] [Abstract][Full Text] [Related]
9. Role of ferroptosis in hepatocellular carcinoma.
Nie J; Lin B; Zhou M; Wu L; Zheng T
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2329-2337. PubMed ID: 30167889
[TBL] [Abstract][Full Text] [Related]
10. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
11. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
12. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
13. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract][Full Text] [Related]
14. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma.
Hao SH; Ma XD; Xu L; Xie JD; Feng ZH; Chen JW; Chen RX; Wang FW; Tang YH; Xie D; Cai MY
Drug Resist Updat; 2024 Mar; 73():101052. PubMed ID: 38262246
[TBL] [Abstract][Full Text] [Related]
15. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
16. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
17. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
18. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
19. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
